Pradefovir mesilate (previously known as MB-06886, Hepavir B and remofovir mesylate) is an orally administered small molecule compound that belongs to a novel series of phosphate and phosphonate prodrugs of... Adefovir (Hepsera) is an acyclic phosphonate analogue of adenine that is used to treat hepatitis B virus.
- Mechanism
- Curator reviewed
Pradefovir is activated through oxidation that is mediated by cytochrome P-450 (CYP) 3A4, which is predominantly expressed in the liver. In this way, it allows for increased Hepsera concentrations selectively in the liver.
- Primary indication
- Investigated for use as a prodrug for Hepsera in treating hepatitis (viral, B).Curator reviewed
- Formula / weight
- C18H23ClN5O7PS · 519.896 g/mol (avg)
- Also known as
- Pradefovir mesilate
- Code names
- MB-06886
Resolves to
JXQUAHHUSMJUFV-HZPZRMRQSA-NSMILESCS(O)(=O)=O.NC1=C2N=CN(CCOC[P@@]3(=O)OCC[C@H](O3)C3=CC(Cl)=CC=C3)C2=NC=N1What you can answer from here — as of February 21, 2021
Which drugs share a target with Pradefovir mesylate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account